DOCSLIB.ORG

The Role of Histone Modifications in the Regulation of Alternative Splicing During Epithelial-To-Mesenchymal Transition Alexandre Segelle

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Histone Modifications in the Regulation of Alternative Splicing During Epithelial-To-Mesenchymal Transition Alexandre Segelle The role of histone modifications in the regulation of alternative splicing during epithelial-to-mesenchymal transition Alexandre Segelle To cite this version: Alexandre Segelle. The role of histone modifications in the regulation of alternative splicing during epithelial-to-mesenchymal transition. Agricultural sciences. Université Montpellier, 2020. English. NNT : 2020MONTT017. tel-03137009 HAL Id: tel-03137009 https://tel.archives-ouvertes.fr/tel-03137009 Submitted on 10 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE M ONTPELLIER En Biologie Moléculaire et Cellulaire École doctorale Sciences Chimiques et Biologiques pour la Santé (ED CBS2 168) Unité de recherche UMR9002 CNRS-UM – Institut de Génétique Humaine (IGH) The role of histone modifications in the regulation of alternative splicing during the epithelial-to-mesenchymal transition Présentée par Alexandre Segelle Le 28 Septembre 2020 Sous la direction de Reini Fernandez de Luco Devant le jury composé de Anne-Marie MARTINEZ, Professeure, Université de Montpellier Présidente du jury Christian MUCHARDT, DR et Chef d’équipe, Institut Pasteur de Paris Rapporteur Juan VALCARCEL, Research Professor et Chef d’équipe, Institut CRG de Barcelone Rapporteur Franck MORTREUX, CR, Institut LBMC de Lyon Examinateur Reini FERNANDEZ DE LUCO, CR et Chef d’équipe, Institut IGH de Montpellier Directrice de thèse The Role of histone modifications in the regulation of alternative splicing during the EMT With the support of – Avec le soutien de: I G H INSTITUTE OF HUMAN GENETICS 1 The Role of histone modifications in the regulation of alternative splicing during the EMT Table of Contents ACKNOWLEDGMENTS - REMERCIEMENTS .............................................................................................. 5 LIST OF FIGURES ...................................................................................................................................... 8 LIST OF TABLES ...................................................................................................................................... 10 ABREVIATIONS ....................................................................................................................................... 11 SUMMARY – SYNTHESE EN FRANCAIS................................................................................................... 13 INTRODUCTION ................................................................................................................................. 15 Chapter 1: RNA splicing, alternative splicing (AS) and underlying mechanisms ........................... 16 1.1 History of splicing .......................................................................................................... 16 1.1.1 Discovery of RNA splicing ...................................................................................... 16 1.1.2 Discovery of alternative splicing ............................................................................ 17 1.2 RNA splicing ................................................................................................................... 18 1.2.1 RNA splicing reaction ............................................................................................. 20 1.2.2 Intron definition .................................................................................................... 22 a Donor site and acceptor site ..................................................................................... 22 b Branch point .............................................................................................................. 23 1.2.3 Spliceosomal complex ........................................................................................... 23 a Spliceosome composition .......................................................................................... 23 b Spliceosome assembling and catalytic activity .......................................................... 25 1.3 Alternative splicing ........................................................................................................ 28 1.3.1 Different alternative splicing events ..................................................................... 28 a Cassette exons ........................................................................................................... 28 b Mutually exclusive exons ........................................................................................... 28 c Alternative 5’ and 3’ splice sites ................................................................................ 29 d Intron retention ......................................................................................................... 30 e Alternative promoters and polyadenylation sites ..................................................... 30 1.3.2 Regulatory elements ............................................................................................. 30 a Cis regulatory elements ............................................................................................. 31 b Trans regulatory elements ........................................................................................ 32 1.4 Deregulation of alternative splicing in cancer ............................................................... 34 1.4.1 Alteration of alternative splicing programs in cancer ........................................... 34 a Alternatively spliced genes in cancer ........................................................................ 34 b Splicing factors in cancer ........................................................................................... 36 1.4.2 Oncogenic and tumor suppressor functions of AS variants .................................. 37 2 The Role of histone modifications in the regulation of alternative splicing during the EMT 1.4.3 Therapeutic strategies based on splicing variants ................................................ 38 Chapter 2: The relationship between chromatin and splicing ...................................................... 40 2.1 Chromatin ...................................................................................................................... 40 2.1.1 Discovery of chromatin ......................................................................................... 40 2.1.2 Chromatin structure .............................................................................................. 40 a Nucleosome ............................................................................................................... 41 b Chromatin higher-order structure ............................................................................. 42 c Euchromatin and heterochromatin ........................................................................... 43 2.1.2 Chromatin: a dynamic structure ............................................................................ 45 a Chromatin remodeling .............................................................................................. 45 b Histone chaperones ................................................................................................... 46 c Histone variants ......................................................................................................... 47 d Histone post-translational modifications .................................................................. 48 e DNA methylation ....................................................................................................... 50 2.2 Genome and epigenome editing: the CRISPR/(d)Cas9 system ..................................... 51 2.2.1 Discovery and description of CRISPR/Cas .............................................................. 51 2.2.2 Genome editing with CRISPR/Cas9........................................................................ 53 2.2.3 CRISPR/dCas9: a powerful tool for chromatin regulation ..................................... 55 a Transcriptional regulation ......................................................................................... 55 b Epigenome editing ..................................................................................................... 55 2.3 Alternative splicing and chromatin signature ............................................................... 56 2.4 Relationship between chromatin, transcription and alternative splicing ..................... 58 2.4.1 Coupling between alternative splicing and transcription ..................................... 59 2.4.2 Chromatin affects alternative splicing ................................................................... 60 a Kinetic model ............................................................................................................. 60 b Recruitment model .................................................................................................... 61 Chapter 3: The epithelial-to-mesenchymal transition (EMT) and its regulation .......................... 63 3.1
Load more

Recommended publications
  • A Prelude to the Proximity Interaction Mapping of CXXC5
    www.nature.com/scientificreports OPEN A prelude to the proximity interaction mapping of CXXC5 Gamze Ayaz1,4,6*, Gizem Turan1,6, Çağla Ece Olgun1,6, Gizem Kars1, Burcu Karakaya1, Kerim Yavuz1, Öykü Deniz Demiralay1, Tolga Can2, Mesut Muyan1,3* & Pelin Yaşar1,5,6 CXXC5 is a member of the zinc-fnger CXXC family proteins that interact with unmodifed CpG dinucleotides through a conserved ZF-CXXC domain. CXXC5 is involved in the modulation of gene expressions that lead to alterations in diverse cellular events. However, the underlying mechanism of CXXC5-modulated gene expressions remains unclear. Proteins perform their functions in a network of proteins whose identities and amounts change spatiotemporally in response to various stimuli in a lineage-specifc manner. Since CXXC5 lacks an intrinsic transcription regulatory function or enzymatic activity but is a DNA binder, CXXC5 by interacting with proteins could act as a scafold to establish a chromatin state restrictive or permissive for transcription. To initially address this, we utilized the proximity-dependent biotinylation approach. Proximity interaction partners of CXXC5 include DNA and chromatin modifers, transcription factors/co-regulators, and RNA processors. Of these, CXXC5 through its CXXC domain interacted with EMD, MAZ, and MeCP2. Furthermore, an interplay between CXXC5 and MeCP2 was critical for a subset of CXXC5 target gene expressions. It appears that CXXC5 may act as a nucleation factor in modulating gene expressions. Providing a prelude for CXXC5 actions, our results could also contribute to a better understanding of CXXC5-mediated cellular processes in physiology and pathophysiology. Te methylation of mammalian genomic DNA, which predominantly arises post-replicatively at the 5’ posi- tion of the cytosine base in the context of CpG dinucleotides, varies across cell types, developmental stages, physiological and pathophysiological conditions 1.
    [Show full text]
  • Role of Cajal Bodies and Nucleolus in the Maturation of the U1 Snrnp in Arabidopsis
    CORE Metadata, citation and similar papers at core.ac.uk Provided by PubMed Central Role of Cajal Bodies and Nucleolus in the Maturation of the U1 snRNP in Arabidopsis Zdravko J. Lorkovic´*, Andrea Barta Max F. Perutz Laboratories, Department of Medical Biochemistry, Medical University of Vienna, Vienna, Austria Abstract Background: The biogenesis of spliceosomal snRNPs takes place in both the cytoplasm where Sm core proteins are added and snRNAs are modified at the 59 and 39 termini and in the nucleus where snRNP-specific proteins associate. U1 snRNP consists of U1 snRNA, seven Sm proteins and three snRNP-specific proteins, U1-70K, U1A, and U1C. It has been shown previously that after import to the nucleus U2 and U4/U6 snRNP-specific proteins first appear in Cajal bodies (CB) and then in splicing speckles. In addition, in cells grown under normal conditions U2, U4, U5, and U6 snRNAs/snRNPs are abundant in CBs. Therefore, it has been proposed that the final assembly of these spliceosomal snRNPs takes place in this nuclear compartment. In contrast, U1 snRNA in both animal and plant cells has rarely been found in this nuclear compartment. Methodology/Principal Findings: Here, we analysed the subnuclear distribution of Arabidopsis U1 snRNP-specific proteins fused to GFP or mRFP in transiently transformed Arabidopsis protoplasts. Irrespective of the tag used, U1-70K was exclusively found in the nucleus, whereas U1A and U1C were equally distributed between the nucleus and the cytoplasm. In the nucleus all three proteins localised to CBs and nucleoli although to different extent. Interestingly, we also found that the appearance of the three proteins in nuclear speckles differ significantly.
    [Show full text]
  • Supplementary Table S1. Upregulated Genes Differentially
    Supplementary Table S1. Upregulated genes differentially expressed in athletes (p < 0.05 and 1.3-fold change) Gene Symbol p Value Fold Change 221051_s_at NMRK2 0.01 2.38 236518_at CCDC183 0.00 2.05 218804_at ANO1 0.00 2.05 234675_x_at 0.01 2.02 207076_s_at ASS1 0.00 1.85 209135_at ASPH 0.02 1.81 228434_at BTNL9 0.03 1.81 229985_at BTNL9 0.01 1.79 215795_at MYH7B 0.01 1.78 217979_at TSPAN13 0.01 1.77 230992_at BTNL9 0.01 1.75 226884_at LRRN1 0.03 1.74 220039_s_at CDKAL1 0.01 1.73 236520_at 0.02 1.72 219895_at TMEM255A 0.04 1.72 201030_x_at LDHB 0.00 1.69 233824_at 0.00 1.69 232257_s_at 0.05 1.67 236359_at SCN4B 0.04 1.64 242868_at 0.00 1.63 1557286_at 0.01 1.63 202780_at OXCT1 0.01 1.63 1556542_a_at 0.04 1.63 209992_at PFKFB2 0.04 1.63 205247_at NOTCH4 0.01 1.62 1554182_at TRIM73///TRIM74 0.00 1.61 232892_at MIR1-1HG 0.02 1.61 204726_at CDH13 0.01 1.6 1561167_at 0.01 1.6 1565821_at 0.01 1.6 210169_at SEC14L5 0.01 1.6 236963_at 0.02 1.6 1552880_at SEC16B 0.02 1.6 235228_at CCDC85A 0.02 1.6 1568623_a_at SLC35E4 0.00 1.59 204844_at ENPEP 0.00 1.59 1552256_a_at SCARB1 0.02 1.59 1557283_a_at ZNF519 0.02 1.59 1557293_at LINC00969 0.03 1.59 231644_at 0.01 1.58 228115_at GAREM1 0.01 1.58 223687_s_at LY6K 0.02 1.58 231779_at IRAK2 0.03 1.58 243332_at LOC105379610 0.04 1.58 232118_at 0.01 1.57 203423_at RBP1 0.02 1.57 AMY1A///AMY1B///AMY1C///AMY2A///AMY2B// 208498_s_at 0.03 1.57 /AMYP1 237154_at LOC101930114 0.00 1.56 1559691_at 0.01 1.56 243481_at RHOJ 0.03 1.56 238834_at MYLK3 0.01 1.55 213438_at NFASC 0.02 1.55 242290_at TACC1 0.04 1.55 ANKRD20A1///ANKRD20A12P///ANKRD20A2///
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
    HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
    [Show full text]
  • The Reaction Mechanism of Cellular U Snrnp Assembly
    The Reaction Mechanism of Cellular U snRNP Assembly Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Ashwin Chari Aus Bangalore (Indien) Würzburg 2009 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. M. Müller 1. Gutachter: Prof. Dr. U. Fischer 2. Gutachter: Prof. Dr. U. Scheer Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Erklärung Erklärung gemäss §4 Absatz 3 der Promotionsordnung der Fakultät für Biologie der Bayerischen Julius-Maximilians-Universität Würzburg vom 15. März 1999 1. Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die angegebenen Quellen und Hilfsmittel benutzt habe. 2. Ich erkläre, dass die vorliegende Dissertation weder in gleicher noch in ähnlicher Form bereits in einem Prüfungsverfahren vorgelegen hat. 3. Ich erkläre, dass ich ausser den mit dem Zulassungsantrag urkundlich vorgelegten Graden keine weiteren akademischen Grade erworben oder zu erwerben versucht habe. Würzburg, 2009 Ashwin Chari Table of Contents 1. Summary 1 2. Zusammenfassung 5 3. Introduction 9 3.1 Principles Governing Macromolecular Complex Assembly in Vivo 9 3.2 Pre-mRNA Splicing 12 3.3 Architecture of Spliceosomal U snRNPs 14 3.4 The Cell Biology of U snRNP Biogenesis 16 3.5 U snRNP Assembly in Vivo is an Active, Factor-Mediated Process 19 3.6 References 22 4. Goals of this Thesis 29 5. Results 31 5.1 Taking an Inventory of the Subunits of the Human SMN-Complex 31 5.2 Definition of the Basic Architecture of the Human SMN-Complex 49 5.3 Mechanistic Aspects of Cellular U snRNP Assembly 65 5.4 Evolution of the SMN-Complex 115 6.
    [Show full text]
  • (Bsc Zoology and Microbiology) Concept of Introns and Exons
    Unit-5 Molecular Biology (BSc Zoology and Microbiology) Concept of introns and exons Most of the portion of a gene in higher eukaryotes consists of noncoding DNA that interrupts the relatively short segments of coding DNA. The coding sequences are called exons. The noncoding sequences are called introns. Intron: An intron is a portion of a gene that does not code for amino acids An intron is any nucleotide sequence within a gene which is represented in the primary transcript of the gene, but not present in the final processed form. In other words, Introns are noncoding regions of an RNA transcript which are eliminated by splicing before translation. Sequences that are joined together in the final mature RNA after RNA splicing are exons. Introns are very large chunks of RNA within a messenger RNA molecule that interfere with the code of the exons. And these introns get removed from the RNA molecule to leave a string of exons attached to each other so that the appropriate amino acids can be encoded for. Introns are rare in genes of prokaryotes. #Look carefully at the diagram above, we have already discussed about the modification and processing of eukaryotic RNA. In which 5’ guanine cap and 3’poly A tail is added. So at that time, noncoding regions i.e. introns are removed. We hv done ths already. Ok Exon: The coding sequences are called Exon. An exon is the portion of a gene that codes for amino acids. In the cells of plants and animals, most gene sequences are broken up by one or more DNA sequences called introns.
    [Show full text]
  • RNA-Protein Interactions of a Kink
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2005 Biophysical and Biochemical Investigation of an Archaeal Box C/D SRNP: RNA- Protein Interactions of a Kink Turn RNA within the Functional Enzyme Terrie Luong Moore Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] THE FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES BIOPHYSICAL AND BIOCHEMICAL INVESTIGATION OF AN ARCHAEAL BOX C/D SRNP: RNA-PROTEIN INTERACTIONS OF A KINK TURN RNA WITHIN THE FUNCTIONAL ENZYME By TERRIE LUONG MOORE A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Summer Semester, 2005 The members of the Committee approve the dissertation of Terrie Luong Moore defended on May 3, 2005. ________________________________ Hong Li Professor Directing Dissertation ________________________________ Lloyd M. Epstein Outside Committee Member ________________________________ Timothy M. Logan Committee Member ________________________________ John G. Dorsey Committee Member Approved: ___________________________________________________ Naresh Dalal, Chair, Department of Chemistry and Biochemistry The Office of Graduate Studies has verified and approved the above named committee members. ii I dedicate this work to my husband, Michael, for being there every step of the way and always giving me hope about the future. Without your love and support, this work would not have been possible. iii ACKNOWLEDGEMENTS I would like to thank my mentor, Dr. Hong Li, first and foremost for taking me into her lab and allowing me to grow intellectually. I would like to thank all of my committee members, Dr.
    [Show full text]
  • A Dissertation Entitled the Androgen Receptor
    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
    [Show full text]
  • Proquest Dissertations
    RICE UNIVERSITY Molecular Basis of Gene Dosage Sensitivity by Jianping Chen A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE Doctor of Philosophy APPROVED, THESIS COMMITTEE: Ariel Fernandez, Chair Karl F. Hasselmann Professor Department of Bioengineering Rice University rn'idtfP h.tQsJUW*- Michael W. Deem, John W. Cox Professor Department of Bioengineering Department of Physics and Astronomy Rice Universit ^engineering at Rice University Jiochemistry at Baylor College of Medicine Axxttig- «J^gb/uv Laura Segaton, T.N. Law Assistant Professor Chemical and Biomolecular Engineering Rice University HOUSTON, TEXAS JANUARY 2009 UMI Number: 3362141 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. UMI® UMI Microform 3362141 Copyright 2009 by ProQuest LLC All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Molecular Basis of Gene Dosage Sensitivity by JianpingChen Deviation of gene expression from normal levels has been associated with diseases. Both under- and overexpression of genes could lead to deleterious biological consequences. Dosage balance has been proposed to be a key issue of determining gene expression pheno- type.
    [Show full text]
  • Upregulation of Erp57 Promotes Clear Cell Renal Cell Carcinoma
    Liu et al. Journal of Experimental & Clinical Cancer Research (2019) 38:439 https://doi.org/10.1186/s13046-019-1453-z RESEARCH Open Access Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop Yan Liu1,2†, Jian-Xing Wang1,3†, Zi-Yuan Nie4, Yue Wen1, Xin-Ju Jia5, Li-Na Zhang1, Hui-Jun Duan1* and Yong-Hong Shi1* Abstract Background: ERp57 dysfunction has been shown to contribute to tumorigenesis in multiple malignances. However, the role of ERp57 in clear cell renal carcinoma (ccRCC) remains unclear. Methods: Cell proliferation ability was measured by MTT and colony forming assays. Western blotting and quantitative real-time PCR (qRT-PCR) were performed to measure protein and mRNA expression. Co-immunoprecipitation (CoIP) and proximity ligation assay (PLA) were performed to detect protein-protein interaction. Chromatin immunoprecipitation (ChIP), ribonucleoprotein immunoprecipitation (RIP), and oligo pull-down were used to confirm DNA–protein and RNA–protein interactions. Promoter luciferase analysis was used to detect transcription factor activity. Results: Here we found ERp57 was overexpressed in ccRCC tissues, and the higher levels of ERp57 were correlated with poor survival in patients with ccRCC. In vivo and in vitro experiments showed that ccRCC cell proliferation was enhanced by ERp57 overexpression and inhibited by ERp57 deletion. Importantly, we found ERp57 positively regulated ILF3 expression in ccRCC cells. Mechanically, ERp57 was shown to bind to STAT3 protein and enhance the STAT3- mediated transcriptional activity of ILF3. Furthermore, ILF3 levels were increased in ccRCC tissues and associated with poor prognosis. Interestingly, we revealed that ILF3 could bind to ERp57 and positively regulate its expression by enhancing its mRNA stability.
    [Show full text]
  • Downloaded with Ma- Disease D D
    bioRxiv preprint doi: https://doi.org/10.1101/483065; this version posted November 29, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. F1000Research 2016 - DRAFT ARTICLE (PRE-SUBMISSION) Bioinformatics Approach to Identify Diseasome and Co- morbidities Effect of Mitochondrial Dysfunctions on the Progression of Neurological Disorders Md. Shahriare Satu1, Koushik Chandra Howlader2, Tajim Md. Niamat Ullah Akhund3, Fazlul Huq4, Julian M.W. Quinn5, and Mohammad Ali Moni4,5 1Dept. of CSE, Gono Bishwabidyalay, Dhaka, Bangladesh 2Dept. of CSTE, Noakhali Science and Technology University, Noakhali, Bangladesh 3Institute of Information Technology, Jahangirnagar University, Dhaka, Bangladesh 4School of Biomedical Science, Faculty of Medicine and Health, The University of Sydney, Australia 5Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia Abstract Mitochondrial dysfunction can cause various neurological diseases. We therefore developed a quantitative framework to explore how mitochondrial dysfunction may influence the progression of Alzheimer’s, Parkinson’s, Hunting- ton’s and Lou Gehrig’s diseases and cerebral palsy through analysis of genes showing altered expression in these conditions. We sought insights about the gene profiles of mitochondrial and associated neurological diseases by investigating gene-disease networks, KEGG pathways, gene ontologies and protein-protein interaction network. Gene disease networks were constructed to connect shared genes which are commonly found between the neurological diseases and Mito- chondrial Dysfunction. We also generated KEGG pathways and gene ontologies to explore functional enrichment among them, and protein-protein interaction networks to identify the shared protein groups of these diseases.
    [Show full text]